

Rheumatoid Arthritis

Juvenile Arthritis

Osteoarthritis

Thecasesolutions.com

JAK inhibitors - Baricitinib (S1111)
 Pfizer (PFI) closed the implementation of an OIG panel for its anti-JAK inhibitor, baricitinib, and the use could be commercialized in the case of drug development under FDCTA. Pfizer's claims, submitted this week after agency selection, had not received approval of FDA's potential biosimilarity (Biosimilarity) for development of baricitinib.

Wilentz, DE based Inpeya has been developing a metformin (MET) combination with drug class B (Lipid/LDL). And the results came from a mid-stage trial that is the drug, it was at 1000000, and a dose that was not at that level. Inpeya is also developing a metformin combination with drug class B (Lipid/LDL). And the results came from a mid-stage trial that is the drug, it was at 1000000, and a dose that was not at that level. Inpeya is also developing a metformin combination with drug class B (Lipid/LDL). And the results came from a mid-stage trial that is the drug, it was at 1000000, and a dose that was not at that level.

Kinase Inhibitors-Jaks and Syk

Kinase Inhibitors-Jaks and Syk
 Kinase Inhibitors-Jaks and Syk
 Kinase Inhibitors-Jaks and Syk

Lupus

Thecasesolutions.com

Gout

Thecasesolutions.com



Thecasesolutions.com

Thecasesolutions.com

Thecasesolutions.com

Spondylarthritis

Spondylarthritis is a group of inflammatory diseases that affect the spine and other parts of the body. It is characterized by pain, swelling, and stiffness in the joints, particularly in the lower back and neck. The condition can also affect the eyes, mouth, and skin.

The disease is caused by an autoimmune response, where the body's immune system attacks its own tissues. This leads to inflammation and damage to the joints and other parts of the body.

Treatment typically involves a combination of medications, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). Physical therapy and exercise can also help to manage symptoms and improve joint function.

From a paper about using immuno-targeting biologics like the ones in RA, for Uveitis->so a lot of crossover from ophthal rheum

Use of Biologic Agents in the Treatment of Uveitis
 Uveitis is a group of inflammatory diseases that affect the eye. It is characterized by pain, redness, and swelling in the eye. The condition can be caused by infection, trauma, or an autoimmune response.

Biologic agents are a class of medications that target specific components of the immune system. They are used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.

In the treatment of uveitis, biologic agents have shown promising results. They can help to reduce inflammation and pain, and improve vision. However, they also carry the risk of infection and other side effects.

Biologic Agent	Target	Indication
Adalimumab	Tumor Necrosis Factor-α	Rheumatoid Arthritis, Psoriasis, Crohn's Disease
Abatacept	CD28	Rheumatoid Arthritis
Anakinra	Interleukin-1	Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis
Etanercept	Tumor Necrosis Factor-α	Rheumatoid Arthritis, Psoriasis, Crohn's Disease
Infliximab	Tumor Necrosis Factor-α	Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis
Rituximab	CD20	Rheumatoid Arthritis, Systemic Lupus Erythematosus, Chronic Immune Thrombocytopenic Purpura
Sulfasalazine	Not a biologic	Rheumatoid Arthritis, Crohn's Disease

Orphan Disorders in the Space

CAPS - Analogue is approved for this an II-1 disorder
 Thecasesolutions.com

Actin?
 Thecasesolutions.com

Sanofi-Aventis's Tender Offer for Genzyme Case Solution

Thecasesolutions.com

Thecasesolutions.com

JAK inhibitors--FierceBio-5/11/12

Pfizer (\$PFE) scored the endorsement of an FDA panel for its arthritis pill tofacitinib this week, and the win could put some wind in the sails of drug developer Incyte (\$INCY). Incyte's shares jumped this week after agency advisers backed approval of Pfizer's potential blockbuster JAK inhibitor for rheumatoid arthritis.

Wilmington, DE-based Incyte has been developing a rival JAK inhibitor in partnership with drug giant Eli Lilly (\$LLY). And the interim data from a mid-stage trial data on the drug, known as LY3009104, are due out next month at the European League Against Rheumatism's Annual European Congress of Rheumatology, according to Incyte. the pipeline, Incyte fits the profile to be gobbled up by a larger company.

Kinase Inhibitors-Jaks and Syk

Incyte-JAK 1 and 2 inhibitors--being tried for RA
Jakafi (ruxolitinib) approved for MF--
myelofibrosis
-->this one gets JAK2 and 1?

Rigel's Syk-Fostamatinib

Galapagos (GLPG0634) with ABBOTT
-->furthest behind but claims to be JAK1 specific

Tofa-Pfizer- AdCom May2012,
PDUFA--August 2012

Vertex-VX-509--JAK3 specific?

Thecasesolutions.com

02.05.2012

Belimumab for lupus erythematosus: added benefit not proven

Drug manufacturer presents no relevant studies for the benefit assessment

Belimumab (trade name Benlysta ®) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody is only considered as treatment when the disease is still active in spite of standard therapy

Anthera's Blisibimod for lupus
Currently ph2b

same MOI as benlysta?

us

ACthar?

- DMPM--Dermatomyositis and polymyositis?--
ACTHAR gel?

Thecasesolutions.com

CAPS---Arcalyst is approved for this--an IL-1 disorder

Thecasesolutions.com

- CAPS--from wiki--Cryopyrin-associated periodic syndrome (CAPS) is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome (FCAS, formerly termed familial cold-induced urticaria), the Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID, also called chronic infantile neurologic cutaneous and articular syndrome or CINCA). They share many clinical features.
- These syndromes are associated with mutations in NLRP3, the gene encoding cryopyrin. This is a component of the interleukin 1 inflammasome, and mutations lead to unregulated production of interleukin 1 β . Monoclonal antibodies against interleukin 1 β (such as canakinumab), other interleukin 1 binding proteins (such as rilonacept), or interleukin 1 receptor antagonist (for example anakinra) can be used to treat these disorders.

RA-REMS

patients with rheumatoid arthritis have twice the risk for cardiovascular mortality as the larger population

RA registries

- CORRONA
- there's a British Registry
- others?

Thecasesolutions.com

RA-Diagnostics

Crescendo Biosciences

- test-Vectra DA

- 12 biomarkers

Thecasesolutions.com

The

Thecasesolutions.com

IL-17 Inhibitors

from Amgen--brodalumab (formerly AMG 827)
an IL-17 inhibitor

- Ph2 -NEJM article
- from press release-The majority of subjects treated with brodalumab 210 mg every other week achieved total clearance of their skin disease (PASI 100 of 62 percent)--so first biologic to show total clearance

from Ely Lilly--Ixekizumab (formerly LY42439821)

- ph2 NEJM article

BOTH of these articles came out in NEJM on March29,2012...will have to see if these are really going head to head, which is better, etc

AND where is Novartis' secukinumab (AIN457)...Ph2, -press release- touting good ph2, oct 2011

what's this 3-way race look like? timing vs efficacy/safety?

JAK inhibitors

-Pfizer's Tofacitinib

- which is a JAK3 inhibitor

-Incytes-INCB28050 (LY3009104)

- a jak1/2 inhibitor

-Vertex's-VX-509

- Jak3

All about the specificity, trying to be more specific to Inflammatory tissue, thus more efficacy and lessen the safety profile

Rigel's Fostamatinib- Syk inhibitor